Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	58066-85-6
Formula :	C₂₁H₄₆NO₄P
M.W :	407.57
SMILES Code :	O=P(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]
Synonyms :	HePC; Hexadecyl phosphocholine; Miltefosinum
MDL No. :	MFCD00133396
InChI Key :	PQLXHQMOHUQAKB-UHFFFAOYSA-N
Pubchem ID :	3599

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H334
Precautionary Statements:	P261-P264-P270-P285-P301+P310-P304+P341-P330-P342+P311-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

Human eosinophils	20 µM	15 min	Inhibited CCL11-stimulated Akt phosphorylation	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Human eosinophils	20 µM	15 min	Inhibited CCL24-induced eosinophil chemotaxis	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Mouse bone marrow-derived eosinophils	20 µM	1 min	Inhibited CCL24-stimulated intracellular calcium flux by approximately 50%, similar to human eosinophils	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Human eosinophils	20 µM	1 min	Inhibited CCL24-stimulated intracellular calcium flux by approximately 50%	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Human eosinophils	20 µM	15 min	Suppressed C5a-induced CD63 expression (0.5 nM) but had no effect at high C5a concentration (100 nM)	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Human eosinophils	20 µM	15 min	Inhibited CCL24-induced CD11b up-regulation by approximately 50%	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Human eosinophils	0.5–20 µM	15 min	Inhibited CCL11-induced eosinophil shape change by approximately 50% at the highest concentration (20 μM)	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Horse erythrocytes	12 µM	20 hours	To assess the effect of miltefosine on the hemolytic activity of A. baumannii strains. Results showed that miltefosine significantly reduced the hemolytic activity of all tested strains.	Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01409-18.
A549 human alveolar epithelial cells	12 µM	20 hours	To assess the effect of miltefosine on the cytolytic activity of A. baumannii strains against A549 cells. Results showed that miltefosine significantly reduced the cytolytic activity of all tested strains.	Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01409-18.
RAW264.7 macrophage cell line	5 µM	24 hours	Assessment of NO accumulation in macrophages post-infection	EBioMedicine. 2022 Dec;86:104378.
Trypanosoma cruzi trypomastigotes	31.17 µM	24 hours	Evaluate the trypanocidal activity of MLT on trypomastigotes, results showed low trypanocidal activity of MLT.	Front Cell Infect Microbiol. 2022 Jul 5;12:855119.
Trypanosoma cruzi trypomastigotes	31.17 µM (IC50)	24 hours	Evaluate the trypanocidal activity of MLT on trypomastigotes, results showed low trypanocidal activity of MLT.	Front Cell Infect Microbiol. 2022 Jul 5;12:855119.
Clonorchis sinensis newly excysted juvenile worms (CsNEJs)	12.5, 25, 50, 100 µM	24, 48, 72 hours	To assess the larvicidal effect of MLT on CsNEJs. Results showed that MLT significantly reduced the viability of CsNEJs at 50 µM and 100 µM concentrations, with 0% survival after 48 hours.	Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0064224.
Clonorchis sinensis metacercariae (CsMC)	12.5, 25, 50, 100 µM	24, 48, 72 hours	To assess the larvicidal effect of MLT on CsMC. Results showed that MLT significantly reduced the viability of CsMC at 50 µM and 100 µM concentrations, with 31.3% and 75% reductions in viability after 72 hours, respectively.	Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0064224.
Leishmania infantum promastigotes	10 µM	3.5 hours or 5.0 hours	Measurement of intracellular miltefosine accumulation levels	EBioMedicine. 2022 Dec;86:104378.
CAR-T cells	15 µM	4 days	Restores CAR-T cell function, enhances glycolytic metabolism and glucose uptake	Cell Rep Med. 2024 Dec 17;5(12):101869.
CCD-18Co	10 µM	48 hours	To evaluate the cytotoxic effect of Miltefosine on normal colon cells, results showed that Miltefosine had no significant toxicity on normal cells at higher concentrations.	Clin Transl Med. 2021 Nov;11(11):e552.
SW480	1 µM	48 hours	To evaluate the cytotoxic effect of Miltefosine on CRC cells, results showed that Miltefosine significantly inhibited the growth of SW480 cells and induced apoptosis.	Clin Transl Med. 2021 Nov;11(11):e552.
DLD1	1 µM	48 hours	To evaluate the cytotoxic effect of Miltefosine on CRC cells, results showed that Miltefosine significantly inhibited the growth of DLD1 cells and induced apoptosis.	Clin Transl Med. 2021 Nov;11(11):e552.
HCT116	1 µM	48 hours	To evaluate the cytotoxic effect of Miltefosine on CRC cells, results showed that Miltefosine significantly inhibited the growth of HCT116 cells and induced apoptosis.	Clin Transl Med. 2021 Nov;11(11):e552.
HT29	1 µM	48 hours	To evaluate the cytotoxic effect of Miltefosine on CRC cells, results showed that Miltefosine significantly inhibited the growth of HT29 cells and induced apoptosis.	Clin Transl Med. 2021 Nov;11(11):e552.
Vero-C76 cells	0.51 µM	5 days	Evaluate the inhibitory activity of MLT on intracellular amastigotes, results showed significant inhibition of amastigotes by MLT.	Front Cell Infect Microbiol. 2022 Jul 5;12:855119.
Vero-C76 cells	0.51 µM (IC50)	5 days	Evaluate the inhibitory activity of MLT on intracellular amastigotes, results showed significant inhibition of amastigotes by MLT.	Front Cell Infect Microbiol. 2022 Jul 5;12:855119.
L. donovani intramacrophagic amastigotes	5.60 µM (EC50)	72 hours	Evaluate the leishmanicidal effects of NFT and MTF alone and in combination on L. donovani intramacrophagic amastigotes, finding a strong synergistic effect for the NFT/MTF 1/30 combination up to 50% fa.	Int J Mol Sci. 2023 Jan 13;24(2):1635.
L. donovani axenic amastigotes	0.63 µM (EC50)	72 hours	Evaluate the leishmanicidal effects of NFT and MTF alone and in combination on L. donovani axenic amastigotes, finding a synergistic effect for the NFT/MTF 1/30 combination.	Int J Mol Sci. 2023 Jan 13;24(2):1635.
Lomentospora prolificans FMR 3569	4 µg/ml	72 hours	Evaluate the inhibitory effect of Miltefosine on Lomentospora prolificans, results showed effective inhibition of fungal growth	Front Cell Infect Microbiol. 2021 Jul 23;11:698662.
Scedosporium dehoogii CBS 117406	4 µg/ml	72 hours	Evaluate the inhibitory effect of Miltefosine on Scedosporium dehoogii, results showed effective inhibition of fungal growth	Front Cell Infect Microbiol. 2021 Jul 23;11:698662.
Scedosporium apiospermum CBS 117407	4 µg/ml	72 hours	Evaluate the inhibitory effect of Miltefosine on Scedosporium apiospermum, results showed effective inhibition of fungal growth	Front Cell Infect Microbiol. 2021 Jul 23;11:698662.
Scedosporium boydii CBS 120157	2 µg/ml	72 hours	Evaluate the inhibitory effect of Miltefosine on Scedosporium boydii, results showed effective inhibition of fungal growth	Front Cell Infect Microbiol. 2021 Jul 23;11:698662.
Scedosporium aurantiacum CBS 136046	2–4 µg/ml	72 hours	Evaluate the inhibitory effect of Miltefosine on Scedosporium aurantiacum, results showed effective inhibition of fungal growth	Front Cell Infect Microbiol. 2021 Jul 23;11:698662.
Cryptococcus gattii ATCC 56990	1 μg/ml	72 hours	To evaluate the effects of miltefosine on Cryptococcus cell ultrastructure, results showed thinner cell walls, reduced capsule, and mitochondrial swelling.	Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00312-18.
Cryptococcus neoformans H99	1 μg/ml	72 hours	To evaluate the effects of miltefosine on Cryptococcus cell ultrastructure, results showed thinner cell walls, reduced capsule, and mitochondrial swelling.	Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00312-18.
Leishmania donovani miltefosine-resistant clone (HePC-R40) promastigotes	69.1 ± 1.1 µM (IC50)	72 hours	To assess the effect of miltefosine on the viability of Leishmania donovani resistant clone promastigotes, showing that miltefosine had no cytotoxic effect at concentrations up to 40 μM, but exhibited cytotoxicity at higher doses.	Antimicrob Agents Chemother. 2004 Mar;48(3):852-9.
Leishmania donovani wild-type promastigotes	13.6 ± 2.0 µM (IC50)	72 hours	To assess the effect of miltefosine on the viability of Leishmania donovani promastigotes, showing that miltefosine inhibits the viability of wild-type promastigotes in a concentration-dependent manner.	Antimicrob Agents Chemother. 2004 Mar;48(3):852-9.

NPG mice	NCI-H226-luciferase CDX model	Intraperitoneal injection	10 mg/kg	Once daily, duration as observed	Enhances the solid tumor clearance ability of CAR-T cells	Cell Rep Med. 2024 Dec 17;5(12):101869.
NSG mice	CRC xenograft model	Intraperitoneal	10 mg/kg	Daily for 21 days	To evaluate the antitumor effect of Miltefosine on CRC xenograft models, results showed that Miltefosine significantly inhibited tumor growth and reduced tumor regrowth potential.	Clin Transl Med. 2021 Nov;11(11):e552.
Galleria mellonella	G. mellonella infection model	Injection	12 μM	Single injection, observed for 5 days	To assess the effect of miltefosine on the survival rate of G. mellonella infected with A. baumannii. Results showed that miltefosine significantly reduced the mortality rate of infected larvae.	Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01409-18.
BALB/c mice	Eosinophil migration model in IL-5 transgenic mice	Oral	20 mg/kg	For three consecutive days	Significantly suppressed CCL24-induced eosinophil migration into bronchoalveolar lavage fluid	Br J Pharmacol. 2021 Mar;178(5):1234-1248.
Syrian golden hamsters	Clonorchis sinensis infection model	Oral	20 mg/kg	Administered at 1 and 4 weeks post-infection	To evaluate the larvicidal and adulticidal effects of MLT in vivo against Clonorchis sinensis. Results showed that MLT significantly reduced worm burden by 36.7% and 46.9% when administered at 1 and 4 weeks post-infection, respectively.	Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0064224.
Swiss mice	Immunosuppressed murine model of systemic/vascular pythiosis	Oral	25 mg/kg	Every 24 hours for 14 days	To evaluate the efficacy of miltefosine in treating systemic pythiosis in immunosuppressed mice, results showed miltefosine did not significantly reduce mortality.	Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01385-18
BALB/cJ mice	Acute infection model	Oral	25, 50, 75, 100 mg/kg/day	Once daily for 20 consecutive days	Evaluate the efficacy of MLT alone or in combination with BZ in acute infection in mice, results showed MLT significantly reduced parasitemia and mortality.	Front Cell Infect Microbiol. 2022 Jul 5;12:855119.
Balb/c mice	L. donovani visceral leishmaniasis model	Oral	10 mg/kg	Daily for 10 days	Evaluate the therapeutic efficacy of the NFT/MTF combination in L. donovani-infected mice, showing significant reduction in parasite load, particularly in thymus and bone marrow.	Int J Mol Sci. 2023 Jan 13;24(2):1635.

{[proInfo.proName]}

CAS No.: 58066-85-6

{[proInfo.proName]}

CAS No.: 58066-85-6

Product Citations

Alternative Products

Product Details of Miltefosine

Safety of Miltefosine

Related Pathways of Miltefosine

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT06514560	Cutaneous Leishmaniases		RECRUITING	2026-12-30	Africa Leprosy, Tuberculosis, ... More >>Rehabilitation and Training (ALERT) Hospital, Addis Abeba, Ethiopia Less <<
NCT02431429	Mucocutaneous Leishmaniasis		COMPLETED	2019-03-01	Funderama, Santa Cruz, Bolivia
NCT02429505	Leishmaniasis		WITHDRAWN	2025-03-20	Fast-Track Drugs and Biologics... More >>, LLC, Poolesville, Maryland, 20837, United States Less <<
NCT02431143	Visceral Leishmaniasis	PHASE2	COMPLETED	2025-09-16	Kacheliba Hospital, Kacheliba,... More >> Rift Valley, West Pokot, 30601, Kenya\|Amudat Hospital, Amudat, Karamoja, Uganda Less <<
NCT02193022	Post Kala Azar Dermal Leishman... More >>iasis Less <<	PHASE3	COMPLETED	2019-06-30	International Centre for Diarr... More >>heal Disease Research, Bangladesh, Dhaka, 1212, Bangladesh Less <<
NCT02429518	Mucocutaneous Leishmaniasis		COMPLETED	2018-03-06	Funderma, Santa Cruz, Bolivia
NCT01050907	Mucosal Leishmaniasis\|Cutaneou... More >>s Leishmaniasis Less <<	PHASE2	COMPLETED	2025-03-15	For this treatment IND, each P... More >>hysician entered patients at his/her own facility. Below data is for protocol central contact:, Bethesda, Maryland, 20852, United States\|NIH, Bethesda, Maryland, 20892, United States Less <<
NCT02687971	Cutaneous Leishmaniasis	PHASE2	COMPLETED	2019-09-10	Programa de Estudios y Control... More >> de Enfermedades Tropicales (PECET), Universidad de Antioquia, Medellin, Colombia\|IMT Alexander Von Humboldt, Lima, Peru Less <<
NCT02427308	Leishmaniasis or Other Uses of... More >> Miltefosine Less <<		RECRUITING	2025-03-26	Fast Track, North Potomac, Mar... More >>yland, United States Less <<
NCT01462500	Cutaneous Leishmaniasis	PHASE4	COMPLETED	2025-12-15	Corporación Centro Internacion... More >>al de entrenamiento e Investigaciónes Médicas, Cali, Valle, 5930, Colombia Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed